Please ensure Javascript is enabled for purposes of website accessibility

3 Top Stocks at Half Price

By Rich Duprey - Updated Apr 6, 2017 at 11:15AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Investors still think highly of these companies, despite their fire-sale prices.

You love buying your shirts when they go on sale. And who can resist a buy-one-get-one-free offer? So when our stocks go on sale, why do we bemoan their low prices?

Smart investors like Warren Buffett or Marty Whitman love it when their stocks are suddenly selling at bargain-basement prices. For them, these companies become no-brainer buys.

The investors in the Motley Fool CAPS community also like a bargain, apparently. Below, you'll find three companies whose shares are selling at least 50% below their 52-week highs, but which still earn high honors from our investor-intelligence database. Consider it a BOGO sale on stocks.

Stock

CAPS Rating (out of 5)

% Off  12-Month High

MELA Sciences (Nasdaq: MELA)

****

50%

Neutral Tandem (Nasdaq: TNDM)

*****

55%

STEC (Nasdaq: STEC)

****

68%

Naturally, we want you to look a bit closer at these stocks before buying. You can get low-priced appliances in the dent-and-ding section of your home-remodeling superstore, but their quality might not be so good. Same thing here: Make sure there's nothing seriously wrong with the company before you plug it into your portfolio.

Take two, they're small
The one thing markets hate is uncertainty. MELA Sciences was hoping the FDA would meet this month to decide the fate of its skin cancer screening device, but the advisory panel needs more time and has pushed the meeting back to November.

MELA took a big hit when the FDA delayed pre-market approval for the MelaFind device because they needed more data. Because it emits light waves to capture images of suspected lesions, and uses a sophisticated algorithm trained on MELA's database, to analyze the images to provide information on whether a biopsy is needed, the device is a significant departure from the methods used by General Electric (NYSE: GE) or Siemens PET/CT scanners and might explain in part why the FDA hesitated.

However, the device is so novel, and there seems to be such great need for it that CAPS member jrusso9722 just doesn't see how the MelaFind cannot be approved:

Since Mela-Find (r), is not a drug, I believe, FDA wonders what criteria to use to approve it. I'll predict FDA will approve it. How in God's name can they not approve an imaging device to identify the most deadly form of skin cancer. They dare not keep it from the public.

A reserve player
Network connection services provider Neutral Tandem has suffered from the analyst community's belief that robust competition from Level 3 Communications (Nasdaq: LVLT) will cut into its revenues. They might not be far off though, because although the wireless carrier switchboard reaffirmed full-year guidance earlier in the year, it missed analyst expectations for the second quarter and now says results will come in at the low end of the forecast. That sort of weakening outlook suggests the competition may just be getting to Neutral Tandem.

CAPS member kmote is as fearless as the nearly 1,100 other members who've rated the company to outperform the broad market averages, believing it will be supported by its hefty cash position:

About half the stock price is cash, take a look at the balance sheet, currently $5.65 per share is cash.

With friends like these
Now that STEC has resolved its ZeusIOPS inventory issues with EMC (NYSE: EMC), the solid-state drive maker is ready to rebound and investors may find that it's time for it to become a truly great investment for them. It seems to be only a matter of when, not if, SSDs supplant traditional drives in corporate storage networks. But STEC's reliance on EMC for the vast bulk of its sales creates concentration risk for investors who may wonder when they next hiccup will come.

STEC has moved to address these concerns by putting in place plans to sell more drives to its other customers, including Oracle (Nasdaq: ORCL), IBM, and Hitachi. That could be why 92% of the CAPS members rating the drive maker see it beating the market, but you can tell us on the STEC CAPS page whether you think it will spin out of control.

Have half a mind
Sign up today for the completely free CAPS service, and tell us whether these stocks are twice as good at half the price.

The Fool owns shares of MELA Sciences, Neutral Tandem, and Oracle. Try any of our Foolish newsletter services today, free for 30 days.

Fool contributor Rich Duprey does not have a financial position in any of the stocks mentioned in this article. You can see his holdings here. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

General Electric Company Stock Quote
General Electric Company
GE
$74.93 (-0.33%) $0.25
Dell EMC Stock Quote
Dell EMC
EMC
Oracle Corporation Stock Quote
Oracle Corporation
ORCL
$76.77 (0.39%) $0.30
Level 3 Communications, Inc. Stock Quote
Level 3 Communications, Inc.
LVLT
Inteliquent, Inc. Stock Quote
Inteliquent, Inc.
IQNT
Strata Skin Sciences, Inc. Stock Quote
Strata Skin Sciences, Inc.
SSKN
$1.06 (-1.85%) $0.02

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
379%
 
S&P 500 Returns
123%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 08/10/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.